Novel Live Attenuated Type 3 Poliomyelitis Vaccines (PATH)
- Generic Name
- Novel Live Attenuated Type 3 Poliomyelitis Vaccines (PATH)
Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
Phase 1
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)Biological: Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- PATH
- Target Recruit Count
- 205
- Registration Number
- NCT04529538
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Pharmaron CPC, Inc., Baltimore, Maryland, United States
🇺🇸University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath